AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT by and between TEKMIRA PHARMACEUTICALS CORPORATION and ALNYLAM PHARMACEUTICALS, INC.License and Collaboration Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT, effective as of May 30, 2008, is made by and between Tekmira Pharmaceuticals Corporation (as successor in interest to INEX Pharmaceuticals Corporation (“INEX”)), a corporation organized and existing under the laws of British Columbia, Canada (“Tekmira”), and Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, U.S.A (“Alnylam”).
AMENDED AND RESTATED CROSS-LICENSE AGREEMENT Between ALNYLAM PHARMACEUTICALS, INC. And PROTIVA BIOTHERAPEUTICS INC. Dated: May 30, 2008Cross-License Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
LICENSE AGREEMENT BETWEEN INEX PHARMACEUTICALS CORPORATION AND ARADIGM CORPORATIONLicense Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
This LICENSE AGREEMENT dated as of the 8th day of December, 2004 between INEX PHARMACEUTICALS CORPORATION, a corporation duly incorporated pursuant to the laws of British Columbia, CANADA, having its principal place of business at 100 – 8900 Glenlyon Parkway, Burnaby, B.C. Canada V5J 5J8 (hereinafter referred to as “INEX”), and ARADIGM CORPORATION, a corporation duly incorporated pursuant to the laws of the State of California, USA, having its principal place of business at 3929 Point Eden Way, Hayward, CA 94545 USA. (hereinafter referred to as “Aradigm”).
DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENTDevelopment, Manufacturing and Supply Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Development, Manufacturing and Supply Agreement (the “Agreement”) is entered into as of January 2, 2009 (the “Effective Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation duly incorporated and existing under the laws of the State of Delaware, U.S.A, (“Alnylam”), and Tekmira Pharmaceuticals Corporation, a corporation duly organized and existing under the laws of the Province of British Columbia, Canada (“Tekmira”).
AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN INEX PHARMACEUTICALS CORPORATION AND HANA BIOSCIENCES, INC.License Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • Washington
INEX PHARMACEUTICALS CORPORATION, a company duly incorporated under the laws of British Columbia having an office at #200 – 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8
SUBLICENSE AGREEMENTSublicense Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
ALNYLAM PHARMACEUTICALS, INC., a corporation duly incorporated under the laws of the State of Delaware and having an office at 300 Third Street, 3rd Floor, Cambridge, MA 02142
EMPLOYMENT AGREEMENTEmployment Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
TEKMIRA PHARMACEUTICALS CORPORATION, a company incorporated under the laws of British Columbia (“the Company”), with offices at 200 - 8900 Glenlyon Parkway, Burnaby, British Columbia (fax: (604) 419-3201)
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED AGREEMENTAgreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 1 TO THE AMENDED AND RESTATED AGREEMENT (this “Amendment No. 1”) is made effective as of May 27, 2009 (this “Amendment No. 1 Effective Date”) by and between TEKMIRA PHARMACEUTICALS CORPORATION (formerly INEX PHARMACEUTICALS CORPORATION), a company duly incorporated under the laws of British Columbia having an office at #200 – 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8 (“TEKMIRA”) and HANA BIOSCIENCES, INC., a company duly incorporated under the laws of Delaware having an office at 7000 Shoreline Court, Suite 370, South San Francisco, CA 94080, U.S.A. (“HANA”) (each of HANA and TEKMIRA a “Party,” and collectively, the “Parties”).
ContractLicense Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
* Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
For good and valuable consideration, the receipt and sufficiency of which each party acknowledges, the parties agree as follows:
ContractSecond Amendment Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
* Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
For good and valuable consideration, the receipt and sufficiency of which each party acknowledges, the parties agree as follows:
ContractAlnylam Sublicense Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
* Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.
SETTLEMENT AGREEMENTSettlement Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • New York
This Settlement Agreement (“Settlement Agreement” or “Agreement”) sets forth the terms upon which Sirna Therapeutics, Inc. (SIRNA) and Merck & Co., Inc. (“MERCK & CO”) and Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc. (collectively “PROTIVA”) agree to settle the litigations pending both before the Superior Court of California, San Francisco County, captioned Protiva Biotherapeutics, Inc. et. al. v. Sirna Therapeutics, Inc., Case No. CGC-06-450694 and before the United States District Court For The Northern District of California, captioned Sirna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc. and Mark J. Murray, Case No. C-06-1361 (MMC) (collectively the “Litigation”). SIRNA, MERCK & CO and PROTIVA are individually referred to in this Agreement as a “Party” and collectively as the “Parties”. This Agreement shall be effective as of October 9, 2007 (“Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
TEKMIRA PHARMACEUTICALS CORPORATION, a company incorporated under the laws of British Columbia (“the Company”), with offices at 100 – 8900 Glenlyon Parkway, Burnaby, British Columbia [fax: (604) 419-3201]
LEASE Canada Lands Company CLC Limited Inex Pharmaceuticals Corporation GLEN LYON Business ParkLease • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
CANADA LANDS COMPANY CLC LIMITED, as LANDLORD, upon and In consideration of the covenants, terms, and conditions contained in this LEASE, hereby demises and leases to INEX PHARMACEUTICALS CORPORATION, as TENANT, those PREMISES shown outlined in red on Schedule 1A attached hereto, located in the BUILDING constructed (or being constructed) on the LAND.
ContractAmendment Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
* Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended
INDEMNITY AGREEMENTIndemnity Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations • British Columbia
TEKMIRA PHARMACEUTICALS CORPORATION, a company duly incorporated under the laws of the Province of British Columbia, and having an office at #200, 8900 Glenlyon Parkway, Burnaby, British Columbia, V5J 5J8
AMENDMENT NO. 2 TO THE AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 3rd, 2011 • Tekmira Pharmaceuticals Corp • Pharmaceutical preparations
This AMENDMENT NO. 2 TO THE AMENDED AND RESTATED LICENSE AGREEMENT (this “Amendment No. 2”) is made effective as of “September 20”, 2010 (the “Amendment No. 2 Effective Date”) by and between TEKMIRA PHARMACEUTICALS CORPORATION (formerly INEX PHARMACEUTICALS CORPORATION), a company duly incorporated under the laws of British Columbia having an office at #100 – 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8 (“Tekmira”) and HANA BIOSCIENCES, INC., a company duly incorporated under the laws of Delaware having an office at 7000 Shoreline Court, Suite 370, South San Francisco, CA 94080, U.S.A. (“Hana”) (each of HANA and TEKMIRA a “Party,” and collectively, the “Parties”).
